Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>ex vivo</i> chemosensitivityEsther Onecha, Rosa Ayala, Yanira Ruiz‐Heredia et al.|British Journal of Haematology|2020Cited by 14
Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 ImmunotherapiesMichael P. Rettig, Jan Davidson‐Moncada, Hélène Lelièvre et al.|Blood|2017Cited by 12
Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasmsAlicia Arenas Cortés, Joaquín Martínez‐López, Rosa Ayala et al.|Haematologica|2018Cited by 9
High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor RuxolitinibAlicia Arenas, Joaquín Martínez‐López, Pilar Hernández-Campo et al.|Blood|2013Cited by 2
Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat MyelofibrosisAlicia Arenas, Joaquín Martínez‐López, Pilar Hernández-Campo et al.|Blood|2014Cited by 1